Wall Street Zen cut shares of Akanda (NASDAQ:AKAN – Free Report) from a sell rating to a strong sell rating in a research note released on Saturday.
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Akanda in a report on Thursday, August 13th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has an average rating of “Sell”.
Read Our Latest Research Report on Akanda
Akanda Stock Performance
Akanda (NASDAQ:AKAN – Get Free Report) last released its quarterly earnings results on Tuesday, June 9th. The company reported ($317.90) EPS for the quarter.
Akanda Company Profile
Akanda Corp., through its subsidiaries, engages in the cultivation, manufacture, and distribution of cannabis products to patients worldwide. It offers medicinal-grade cannabis and cannabis based medical and wellness products. The company was incorporated in 2021 and is headquartered in New Romney, the United Kingdom.
Read More
- Five stocks we like better than Akanda
- From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens
- These 3 GARP Stocks Show Why Growth and Value Do Not Have to Clash
- Venture Into High-Volatility Corners of the Market With These 3 ETFs
- 3 Retail Stocks to Watch After a Big Consumer Earnings Week
Receive News & Ratings for Akanda Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akanda and related companies with MarketBeat.com's FREE daily email newsletter.
